Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism.

Dysregulation of lipid metabolism is a key feature of metabolic disorder related to side effects of antipsychotic drugs. Here, we investigated the molecular mechanism by which second-generation atypical antipsychotic drugs (AAPDs) affect hepatic lipid metabolism in liver. AAPDs augmented hepatic lipid accumulation by activating expression of sterol regulatory element-binding protein (SREBP) transcription factors, with subsequent induction of downstream target genes involved in lipid and cholesterol synthesis in hepatocytes. We confirmed the direct involvement of SREBPs on AAPD-induced expression of lipogenic and cholesterogenic genes by utilization of adenovirus for dominant negative SREBP (Ad-SREBP-DN). Interestingly, AAPDs significantly decreased phosphorylation of AMPKα and expression of fatty acid oxidation genes. Treatment of constitutive active AMPK restored AAPD-mediated dysregulation of genes involved in both lipid synthesis and fatty acid oxidation. Moreover, AAPDs decreased transcriptional activity of PPARα, a critical transcriptional regulator for controlling hepatic fatty acid oxidation, via an AMPK-dependent manner. Close investigations revealed that mutations at the known p38 MAPK phosphorylation sites (S6/12/21A), but not mutations at the putative AMPKα phosphorylation sites (S167/373/453A), block AAPD-dependent reduction of PPARα transcriptional activity, suggesting that p38 MAPK might be also involved in the regulatory pathway as a downstream effector of AAPDs/AMPK. Taken together, these data suggest that AAPD-stimulated hepatic dysregulation of lipid metabolism could result from the inhibition of AMPK activity, and pharmaceutical means to potentiate AMPK activity would contribute to restore hepatic lipid homeostasis that occurs during AAPD treatment.

[1]  S. Obici,et al.  Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance , 2010, Diabetes.

[2]  Young-sil Yoon,et al.  Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. , 2010, Cell metabolism.

[3]  Shijie Li,et al.  Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis , 2010, Proceedings of the National Academy of Sciences.

[4]  Young-sil Yoon,et al.  Adiponectin and thiazolidinedione targets CRTC2 to regulate hepatic gluconeogenesis , 2009, Experimental & Molecular Medicine.

[5]  Young-sil Yoon,et al.  Salt-inducible Kinase Regulates Hepatic Lipogenesis by Controlling SREBP-1c Phosphorylation* , 2009, Journal of Biological Chemistry.

[6]  M. Montminy,et al.  TORC2 regulates hepatic insulin signaling via a mammalian phosphatidic acid phosphatase, LIPIN1. , 2009, Cell metabolism.

[7]  J. Hebebrand,et al.  Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. , 2009, Journal of psychiatric research.

[8]  J. Park,et al.  Alpha‐lipoic acid decreases hepatic lipogenesis through adenosine monophosphate‐activated protein kinase (AMPK)‐dependent and AMPK‐independent pathways , 2008, Hepatology.

[9]  R. Coccurello,et al.  Olanzapine (LY170053, 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5] Benzodiazepine), but Not the Novel Atypical Antipsychotic ST2472 (9-Piperazin-1-ylpyrrolo[2,1-b][1,3]benzothiazepine), Chronic Administration Induces Weight Gain, Hyperphagia, and Metabolic Dysregulation in Mice , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  Xu-Feng Huang,et al.  The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. , 2008, The international journal of neuropsychopharmacology.

[11]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[12]  G. Marsicano,et al.  Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. , 2008, Cell metabolism.

[13]  Yen-Hui Chen,et al.  Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. , 2007, Pharmacological research.

[14]  M. Rzewuska.  [Metabolic risk during antipsychotic treatment in patients with schizophrenia]. , 2007, Psychiatria polska.

[15]  A. Windemuth,et al.  A clinical study of the association of antipsychotics with hyperlipidemia , 2007, Schizophrenia Research.

[16]  D. Rader.  Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. , 2007, The American journal of medicine.

[17]  S. Snyder,et al.  Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase , 2007, Proceedings of the National Academy of Sciences.

[18]  M. J. Yoon,et al.  Adiponectin Increases Fatty Acid Oxidation in Skeletal Muscle Cells by Sequential Activation of AMP-Activated Protein Kinase, p38 Mitogen-Activated Protein Kinase, and Peroxisome Proliferator–Activated Receptor α , 2006, Diabetes.

[19]  B. Viollet,et al.  Activation of AMP‐activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders , 2006, The Journal of physiology.

[20]  J. Shyy,et al.  Sterol regulatory element-binding protein 1 is negatively modulated by PKA phosphorylation. , 2006, American journal of physiology. Cell physiology.

[21]  V. Steen,et al.  SREBP Activation by Antipsychotic- and Antidepressant-Drugs in Cultured Human Liver Cells: Relevance for Metabolic Side-Effects? , 2006, Molecular and Cellular Biochemistry.

[22]  R. Coccurello,et al.  Chronic administration of olanzapine induces metabolic and food intake alterations: a mouse model of the atypical antipsychotic-associated adverse effects , 2006, Psychopharmacology.

[23]  Joseph L. Goldstein,et al.  Protein Sensors for Membrane Sterols , 2006, Cell.

[24]  M. Montminy,et al.  The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism , 2005, Nature.

[25]  E. Berry,et al.  Endocannabinoids and liver disease – review , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[26]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[27]  K. Mackie,et al.  Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. , 2005, The Journal of clinical investigation.

[28]  B. Viollet,et al.  Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. , 2005, Diabetes.

[29]  J. Bar-Tana,et al.  Kinase-independent transcriptional co-activation of peroxisome proliferator-activated receptor alpha by AMP-activated protein kinase. , 2004, The Biochemical journal.

[30]  D. Crabb,et al.  The role of AMP-activated protein kinase in the action of ethanol in the liver. , 2004, Gastroenterology.

[31]  Mengwei Zang,et al.  AMP-activated Protein Kinase Is Required for the Lipid-lowering Effect of Metformin in Insulin-resistant Human HepG2 Cells* , 2004, Journal of Biological Chemistry.

[32]  M. Prentki,et al.  AMP kinase and malonyl-CoA: targets for therapy of the metabolic syndrome , 2004, Nature Reviews Drug Discovery.

[33]  J. Reddy,et al.  Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. , 2003, Current molecular medicine.

[34]  J. W. Rush,et al.  AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. , 2003, American journal of physiology. Endocrinology and metabolism.

[35]  D. Umbricht,et al.  Atypical antipsychotics in the treatment of schizophrenia. , 2003, Swiss medical weekly.

[36]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[37]  R. Nicoll,et al.  Endocannabinoid Signaling in the Brain , 2002, Science.

[38]  Young-Bum Kim,et al.  Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature.

[39]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[40]  D. Azzout-Marniche,et al.  AMP-activated protein kinase and hepatic genes involved in glucose metabolism. , 2001, Biochemical Society transactions.

[41]  F. Kuhajda,et al.  Metformin reverses fatty liver disease in obese, leptin-deficient mice , 2000, Nature Medicine.

[42]  B. Spiegelman,et al.  ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. , 1996, Genes & development.

[43]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[44]  S. Jamdar,et al.  Glycerolipid biosynthesis in rat adipose tissue. 7. Effect of age, site of adipose tissue and cell size. , 1981, Biochimica et biophysica acta.

[45]  S. Jamdar.  Glycerolipid biosynthesis in rat adipose tissue. Influence of adipose-cell size and site of adipose tissue on triacylglycerol formation in lean and obese rats. , 1978, The Biochemical journal.

[46]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.

[47]  S. Schinner,et al.  Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice , 2009 .

[48]  T. Nagamine.  Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. , 2008, Internal medicine.

[49]  V. Steen,et al.  Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? , 2005, The Pharmacogenomics Journal.